Summary & Overview
HCPCS Level II J0689: Cefazolin Sodium Injection, 500 mg
HCPCS Level II code J0689 denotes a 500 mg injection of cefazolin sodium (Baxter), identified as not therapeutically equivalent to J0690. This code is used to bill for the drug product when administered parenterally and is relevant across inpatient and outpatient settings where intravenous antibiotics are provided, including hospital outpatient departments, emergency departments, ambulatory surgical centers, and infusion clinics. Nationally, accurate coding of injectable antibiotics affects clinical documentation, payer adjudication, and antimicrobial stewardship efforts.
Key payers in the scope of typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers of this publication will find a concise overview of the clinical context for cefazolin administration, typical sites of service, and the billing considerations tied to product-specific HCPCS Level II coding. The report outlines common payer coverage patterns, benchmark metrics where available, and relevant policy updates that can influence reimbursement and claim processing for parenteral cefazolin. It also provides practical guidance on documentation elements tied to drug-specific coding and highlights implications for hospital outpatient and ambulatory care billing workflows.
Data not available in the input for specific payor rates, taxonomies, ICD-10 pairings, and related codes; those items are noted as unavailable where applicable.
Billing Code Overview
HCPCS Level II code J0689 represents an injection of cefazolin sodium (Baxter), 500 mg, specified as not therapeutically equivalent to J0690. The service type is drug administration via injection. The typical site of service for this injectable antibiotic is outpatient infusion settings, hospital outpatient departments, emergency departments, and ambulatory surgical centers, where parenteral antibiotics are provided for surgical prophylaxis or treatment of susceptible infections.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old male with a history of diabetes mellitus presents to the outpatient infusion suite for perioperative antimicrobial prophylaxis prior to an elective orthopedic procedure. The surgeon orders intravenous cefazolin sodium supplied by Baxter, dosed at 500 mg for administration in the preoperative holding area. Nursing confirms allergy history (no beta-lactam anaphylaxis), inserts an IV access, reconstitutes and verifies the J0689 vial, documents lot and expiration, and administers the dose 30–60 minutes prior to skin incision. Postadministration, the patient is observed for 15–30 minutes for immediate hypersensitivity and then transported to the operating room. In another common scenario, a patient with a soft tissue infection is treated in an ambulatory infusion center with intermittent IV doses of cefazolin sourced from the facility’s pharmacy using J0689; the pharmacist prepares the dose under aseptic technique and the nurse documents administration in the electronic health record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | Report when part of the drug/biological is discarded after opening or preparation and billing the full unit. |